Tempus offers a comprehensive portfolio for MRD and monitoring, which includes a liquid and tissue based assay to support drug development, including patient stratification for future trials, clinical trial …

Beyond risk stratification, MRD testing may be increasingly used as an additional data point to inform adjuvant treatment decision-making, particularly for patients with ambiguous indications for …

Our portfolio of tumor-naive and tumor-informed minimal residual disease (MRD) and monitoring assays provides physicians with valuable patient insights to individualize treatment plans.

Customize testing with add-ons such as liquid biopsy, hereditary testing, and MRD and monitoring assays, while maintaining the flexibility to order individual tests as needed.

Tempus received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-Low EF (ejection fraction) software, which uses AI to identify certain patients who may have a …

Tempus offers a robust portfolio of tests—from germline and somatic testing to MRD and treatment response monitoring—providing a complete patient view to support clinical decisions.

May 31, 2024 · Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the …

Sep 15, 2025 · This white paper offers a practical overview of MRD testing, covering ctDNA detection, tumor-informed vs. tumor-naive approaches, and its role in cancer surveillance and recurrence risk …

Our comprehensive approach checks hundreds of genes for alterations by testing both the tumor tissue DNA and the normal tissue DNA along with testing the RNA. By testing all three together, we …

Minimal residual disease (MRD) testing can detect ctDNA that may be present after treatment, such as surgery or chemotherapy. This can help your doctor understand if there is any remaining disease …